Home Conferences Contact Us Continuing Education Jobs Weekly News Archives Readership Profile

Monthly News Archives Pharmacy Awards Search Site Search Magazine Archives Submit a Classified Advertisement



11 January 2002 News Update


The 72,000 New Zealanders taking the blood pressure drug Inhibace (cilazapril) are the main beneficiaries of an agreement between Pharmac and Roche that will see the drug continue to be fully subsidised.

The funding of Inhibace is part of a provisional multi-product agreement with Roche.

The proposed agreement covers five products and if ratified, will also see Pharmac listing a drug for the treatment of heart failure, and another drug for treating patients with kidney failure.

The new heart failure drug is the beta-blocker Dilatrend (carvedilol) and the treatment for anaemia in renal patients is Recormon (erythropoietin beta), in injection form.

The proposed agreement involves significant savings in the region of $24 million over five years.

The consultation period closes on January 18, and after considering feedback, Pharmac will make its decision.

Back to welcome page

Back to news archives


Complete this month's questionnaire to qualify for extra Continuing Education credits. Click here
For the answers to last month's quiz click here.


Click here to find out who the winners are for the Pharmacy Today/Zuellig Pharma Pharmacy Awards 2002. Also view and purchase photos of the Awards.


For the leading stories in our latest issue of Pharmacy Today magazine visit our welcome page.


To subscribe to Pharmacy Today, or to purchase The Beauty Manual or The Pharmacy Healthcare Handbook click here.

Job vacancies, items for sale, business opportunities and more.
Updated weekly.
click here.

Consumer Health Information

New Zealand Doctor Online